Guidance

Recommendations

Recommendations

People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care.

Making decisions using NICE guidelines explains how we use words to show the strength (or certainty) of our recommendations, and has information about prescribing medicines (including off‑label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding.

1.1 Managing an acute exacerbation of COPD with antibiotics

1.1.1

Be aware that:

Treatment

1.1.2

Consider an antibiotic (see the recommendations on choice of antibiotic) for people with an acute exacerbation of COPD, but only after taking into account:

  • the severity of symptoms, particularly sputum colour changes and increases in volume or thickness beyond the person's normal day-to-day variation

  • whether they may need to go into hospital for treatment (see the NICE guideline on COPD in over 16s)

  • previous exacerbation and hospital admission history, and the risk of developing complications

  • previous sputum culture and susceptibility results

  • the risk of antimicrobial resistance with repeated courses of antibiotics.

1.1.3

If a sputum sample has been sent for culture and susceptibility testing (in line with the NICE guideline on COPD in over 16s) and an antibiotic has been given:

  • review the choice of antibiotic when results are available and

  • only change the antibiotic according to susceptibility results if bacteria are resistant and symptoms are not already improving (using a narrow-spectrum antibiotic wherever possible).

1.1.4

If an antibiotic is given, give advice:

  • about possible adverse effects of the antibiotic, particularly diarrhoea

  • that symptoms may not be fully resolved when the antibiotic course has been completed

  • about seeking medical help if:

    • symptoms worsen rapidly or significantly or

    • symptoms do not start to improve within 2 to 3 days (or other agreed time) or

    • the person becomes systemically very unwell.

1.1.5

If no antibiotic is given, give advice about:

  • an antibiotic not being needed currently

  • seeking medical help without delay if:

    • symptoms (such as sputum colour changes and increases in volume or thickness) worsen rapidly or significantly or

    • symptoms do not start to improve within an agreed time or

    • the person becomes systemically very unwell.

Reassessment

1.1.6

Reassess people with an acute exacerbation of COPD if their symptoms worsen rapidly or significantly at any time, taking account of:

  • other possible diagnoses, such as pneumonia

  • any symptoms or signs suggesting a more serious illness or condition, such as cardiorespiratory failure or sepsis

  • previous antibiotic use, which may have led to resistant bacteria.

    Send a sputum sample for culture and susceptibility testing if symptoms have not improved following antibiotic treatment and this has not been done already.

Referral and seeking specialist advice

1.1.7

Refer people with an acute exacerbation of COPD to hospital if they have any symptoms or signs suggesting a more serious illness or condition (for example, cardiorespiratory failure or sepsis) and in line with the NICE guideline on COPD in over 16s.

1.1.8

Seek specialist advice for people with an acute exacerbation of COPD if they:

  • have symptoms that are not improving with repeated courses of antibiotics or

  • have bacteria that are resistant to oral antibiotics or

  • cannot take oral medicines (to explore locally available options for giving intravenous antibiotics at home or in the community, rather than in hospital, where appropriate).

For a short explanation of why the committee made these recommendations, see the evidence and committee discussion on antibiotics.

Full details of the evidence and the committee's discussion are in the evidence review.

1.2 Choice of antibiotic

1.2.1

When prescribing an antibiotic for an acute exacerbation of COPD, follow table 1 for adults aged 18 years and over.

1.2.2

Give oral antibiotics first line if the person can take oral medicines, and the severity of their exacerbation does not require intravenous antibiotics.

1.2.3

Review intravenous antibiotics by 48 hours and consider stepping down to oral antibiotics where possible.

Table 1 Antibiotic treatment for adults aged 18 years and over
Treatment Antibiotic, dosage and course length

First-choice oral antibiotics (empirical treatment or guided by most recent sputum culture and susceptibilities)

Amoxicillin:

500 mg three times a day for 5 days (see the BNF for amoxicillin dosage in severe infections)

Doxycycline:

200 mg on first day, then 100 mg once a day for 5‑day course in total (see the BNF for doxycycline dosage in severe infections)

Clarithromycin:

500 mg twice a day for 5 days

Second-choice oral antibiotics (no improvement in symptoms on first choice taken for at least 2 to 3 days; guided by susceptibilities when available)

Use alternative first choice (from a different class)

Alternative choice oral antibiotics (if person at higher risk of treatment failure; guided by susceptibilities when available)

Co‑amoxiclav:

500/125 mg three times a day for 5 days

Co‑trimoxazole:

960 mg twice a day for 5 days

Levofloxacin (only if other alternative choice antibiotics are unsuitable; with specialist advice):

500 mg once a day for 5 days

See the MHRA January 2024 advice on restrictions and precautions for using fluoroquinolone antibiotics because of the risk of disabling and potentially long-lasting or irreversible side effects. Fluoroquinolones must now only be prescribed when other commonly recommended antibiotics are inappropriate

First-choice intravenous antibiotics (if unable to take oral antibiotics or severely unwell; guided by susceptibilities when available)

Amoxicillin:

500 mg three times a day (see the BNF for amoxicillin dosage in severe infections)

Co‑amoxiclav:

1.2 g three times a day

Clarithromycin:

500 mg twice a day

Co‑trimoxazole:

960 mg twice a day (see the BNF for co-trimoxazole dosage in severe infections)

Piperacillin with tazobactam:

4.5 g three times a day (see the BNF for piperacillin with tazobactam dosage in severe infections)

Second-choice intravenous antibiotics

Consult a local microbiologist; guided by susceptibilities

See the BNF for appropriate use and dosing in specific populations, for example, in hepatic impairment, renal impairment, and when administering intravenous antibiotics.

If a person is having antibiotic prophylaxis, treatment should be with an antibiotic from a different class.

Review intravenous antibiotics by 48 hours and consider stepping down to oral antibiotics where possible.

People who may be at a higher risk of treatment failure include people who have had repeated courses of antibiotics, a previous or current sputum culture with resistant bacteria, or people at higher risk of developing complications.

Co‑trimoxazole should only be considered for use in acute exacerbations of COPD when there is bacteriological evidence of sensitivity and good reason to prefer this combination to a single antibiotic (BNF, co-trimoxazole, October 2018).

For a short explanation of why the committee made these recommendations, see the evidence and committee discussion on choice of antibiotics and antibiotic course length.

Full details of the evidence and the committee's discussion are in the evidence review.